Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology

3 years ago

BOSTON, Mar. 30, 2015  — Columbia Laboratories, Inc. (Nasdaq: CBRX), a specialty pharmaceutical company focused on the development of therapeutics for women’s health, has licensed exclusive worldwide rights to a novel intra-vaginal ring (“IVR”) technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring.
This technology was developed by renowned scientists Dr. Robert Langer from the Massachusetts Institute of Technology (“MIT”) and Dr. William Crowley from Massachusetts General Hospital (“MGH”) and Harvard Medical School (“HMS”). Under separate agreements, Drs. Langer and Crowley have joined the Company as strategic advisors to support the deployment of this technology and guide development of future product candidates.

“This technology affords the opportunity to expand intra-vaginal delivery of drugs to include larger molecules, such as peptides, alone and in combination,” said Dr. Robert S. Langer, the MIT Department of Chemical Engineering David H. Koch Institute Professor and one of four living individuals who have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation, the nation’s highest scientific honors.

“A self-administered vaginal ring provides patients with a simplified drug delivery system and should improve compliance and therefore treatment effectiveness,” said Dr. William F. Crowley, the Daniel K. Podolsky Professor of Medicine at HMS, Chief of the Reproductive Endocrine Unit of the Department of Medicine at MGH, and Director of the Harvard-wide Reproductive Endocrine Sciences Center, one of the eight Centers of Excellence in Translational Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Currently available IVRs have simplified the delivery of medicine and are convenient and discrete however, few diseases or conditions have been addressed due to technological limitations. Challenges include drug solubility, molecular characteristics and desired controlled release profiles.

Due to its unique polymer composition and segmentation capability, the segmented IVR developed by Drs. Crowley and Langer has the ability to deliver drugs at different dosages and release rates within a single ring system. Drugs such as progesterone and leuprolide have already been tested using the technology and demonstrated sustained release for up to three weeks. The Company has identified a number of product concepts that could address large market segments and will be prioritizing development of the first candidates in the coming months.
“This novel drug delivery technology aligns perfectly with our strategy to develop proprietary products targeting areas of unmet medical need in women, and we see numerous new product and life cycle management opportunities for it,” said Frank Condella, Columbia’s President and Chief Executive Officer. “We look forward to combining the expertise of Drs. Langer and Crowley with the in-house formulation and drug development capability of our Molecular Profiles, Ltd. subsidiary to bring important new medicines to women.”

Columbia has agreed to minimum annual expenditures to develop products using the vaginal ring technology, and will make milestone-based payments to MGH/MIT when various stages of product development and commercialization are achieved. The Company will also share a portion of any royalties or sublicense revenues received from products utilizing the segmented IVR technology with MGH and MIT.

About Molecular Profiles Ltd.
Molecular Profiles Ltd., a wholly owned subsidiary of Columbia Laboratories, Inc., is a contract development and manufacturing organisation (CDMO) that specializes in pharmaceutical development and production. Its early phase services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist knowledge on developing challenging molecules and complex compounds. Molecular Profiles is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company’s services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe. For more information please visit www.molprofiles.co.uk